---
title: "DERM.US (DERM.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DERM.US/news.md"
symbol: "DERM.US"
name: "DERM.US"
parent: "https://longbridge.com/en/quote/DERM.US.md"
datetime: "2026-03-09T05:41:49.273Z"
locales:
  - [en](https://longbridge.com/en/quote/DERM.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DERM.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DERM.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/DERM.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/DERM.US/news.md)


# DERM.US (DERM.US) — Related News

### [Journey Energy Lifts Reserve Value to Record $1 Billion Despite Lower Price Outlook](https://longbridge.com/en/news/276809801.md)
*2026-02-25T01:11:03.000Z*
> Journey Energy Inc. reported a record net asset value of $1 billion, or $14.17 per share, despite lower oil and gas pric

### [Arlington Dermatology Clinic in Dallas-Fort Worth joins Epiphany Dermatology, expanding the company's presence in TX market. Mary Adams MD has been providing dermatologic care since 1994.](https://longbridge.com/en/news/275341616.md)
*2026-02-09T15:34:15.000Z*
> Epiphany Dermatology has expanded its presence in the Dallas-Fort Worth area by partnering with Arlington Dermatology Cl

### [10:07 ET
			
			
				Ezderm Unveils Platform Evolution: Introduces 'Eve' AI Ecosystem and 'Compass' Clinical Interface](https://longbridge.com/en/news/273392627.md)
*2026-01-22T15:08:44.000Z*
> Ezderm has announced a significant evolution of its platform with the introduction of 'Eve', an AI ecosystem, and 'The C

### [Sheets Smith Investment Management Invests $946,000 in Journey Medical Corporation $DERM](https://longbridge.com/en/news/270300330.md)
*2025-12-19T11:52:22.000Z*
> Sheets Smith Investment Management acquired 132,904 shares of Journey Medical Corporation, valued at approximately $946,

### [Journey Medical Reports Emrosi Shows No Impact on Microbiome in Phase 1 Trial](https://longbridge.com/en/news/269236806.md)
*2025-12-10T13:30:15.000Z*
> Journey Medical Corporation announced Phase 1 trial results for Emrosi™ (DFD-29), showing no impact on skin, gastrointes

### [FY2025 EPS Forecast for Journey Medical Decreased by Analyst](https://longbridge.com/en/news/266138364.md)
*2025-11-17T07:45:33.000Z*
> HC Wainwright has decreased its FY2025 EPS forecast for Journey Medical to ($0.53) from ($0.45), maintaining a "Buy" rat

### [B. Riley Increases Earnings Estimates for Journey Medical](https://longbridge.com/en/news/266042149.md)
*2025-11-15T18:04:03.000Z*
> B. Riley analysts have increased their FY2029 EPS estimates for Journey Medical to $0.93 from $0.85. The stock has a con

### [Journey Medical Corporation Reports Strong Q3 2025 Growth](https://longbridge.com/en/news/266009430.md)
*2025-11-15T04:05:22.000Z*
> Journey Medical Corporation reported strong Q3 2025 growth with net revenues of $17.6 million, a 21% increase from the p